Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer

44Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Platinum-based adjuvant chemotherapy improves survival among patients with lung tumors, in particular non-small cell lung cancer (NSCLC). But the predicament of drug resistance in NSCLC patients is frustrating us. The profiles of microRNAs are different between platinum chemotherapy resistant and sensitive NSCLC cells. Researches regarding microRNAs and their targets, in platinum drug resistant cases, illuminate novel ideals for platinum-based chemotherapy for NSCLC patients. Therefore, in this review we will focus on three aspects: Epithelial-mesenchymal transition (EMT), cell proliferation and apoptosis, and the roles of microRNAs in cisplatin (CDDP) and carboplatin (CBP) resistance.

Cite

CITATION STYLE

APA

Zang, H., Peng, J., Wang, W., & Fan, S. (2017). Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer. Journal of Cancer. Ivyspring International Publisher. https://doi.org/10.7150/jca.21267

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free